Modelling the Financial Framework of the Pharmacotherapy Cost of Rare Diseases with Orphan Medicines

Journals Menu

Follow SCIRP

ISSN Print: 2152-7245
ISSN Online: 2152-7261
www.scirp.org/journal/me
E-mail: me@scirp.org

"Modelling the Financial Framework of the Pharmacotherapy Cost of Rare Diseases with Orphan Medicines—Part II"
written by Albena Zlatareva, Konstantin Tachkov, Milena Stoicheva, Svetla Georgieva, Maria Krasteva Bozhkova, Guenka Petrova,
published by Modern Economy, Vol.5 No.5, 2014

has been cited by the following article(s):

[1]	Clinical and economic assessment of nusinersen: the Bulgarian perspective
	2020

[2]	Orphan medicinal products' access to the Bulgarian pharmaceutical market–challenges and obstacles
	Expert Opinion on Orphan Drugs, 2018

[3]	СЪЩНоСт И ИзПоЛзвАНЕ НА ИкоНоМИЧЕСкИ АНАЛИзИ ПРИ ПРовЕЖДАНЕ НА НАУЧНоИзСЛЕДовАтЕЛСкА РАзРАботкА
	Тзуни

Follow SCIRP

Free SCIRP Newsletters

Add your e-mail address to receive free newsletters from SCIRP.

Top

[1]	Clinical and economic assessment of nusinersen: the Bulgarian perspective Expert Opinion on Orphan Drugs, 2020 DOI:10.1080/21678707.2020.1835641

[2]	Orphan medicinal products’ access to the Bulgarian pharmaceutical market – challenges and obstacles Expert Opinion on Orphan Drugs, 2017 DOI:10.1080/21678707.2018.1421063